Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand

Theratechnologies

09/07/2025 12:45

Overview

Theratechnologies Q2 revenue of $17.7 mln beats analyst expectations, per LSEG data

Net loss for Q2 was $4.46 mln, missing analyst estimates, per LSEG data

Co entered definitive agreement to be acquired by Future Pak affiliate

Outlook

Theratechnologies withdraws Fiscal 2025 revenue and EBITDA guidance, due to Future Pak deal

Company plans to launch EGRIFTA WR, improved version of medication for HIV in Q3 2025.

Theratechnologies sees strong demand for EGRIFTA SV and Trogarzo.

Company anticipates growth contingent on reimbursement and supply chain.

Result Drivers

SUPPLY DISRUPTION - EGRIFTA SV sales declined due to supply disruption, impacting revenue negatively

STRONG DEMAND - Record high patient enrollments for EGRIFTA SV indicate strong demand, per CEO Paul Lévesque

TROGARZO SALES - Increased Trogarzo sales driven by higher unit sales and selling prices

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$17.70 mln
$17.50 mln (2 Analysts)
Q2 Net Income
Miss
-$4.46 mln
-$866,000 (2 Analysts)
Q2 Adjusted EBITDA
Beat
$906,000
-$172,000 (1 Analyst)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Theratechnologies Inc is C$5.53, about 22.2% above its July 8 closing price of C$4.30

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNX21pNVj

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)